Information Provided By: 
Fly News Breaks for November 9, 2018
AIMT
Nov 9, 2018 | 07:16 EDT
Cantor Fitzgerald analyst William Tanner believes the Ramses data support the safety and tolerability of Aimmune Therapeutics' AR101. Aimmune reported that "approximately" 80% of subjects treated with AR101 were able to complete the six-month study, a rate that is similar to that for the Phase 3 Palisade trial, Tanner tells investors in a research note. He keeps an Overweight rating on Aimmune with a $62 price target.
News For AIMT From the Last 2 Days
There are no results for your query AIMT
